Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in MCI or Mild Dementia
NCT04658654Phase 2Unknown
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roflumilast in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by Maastricht University Medical Center+. Primary endpoint: Verbal Learning Test (15 words) at 24 weeks. Status: unknown.
02
Drugs
roflumilast
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04658654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658654.